{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:39:00Z","timestamp":1765370340664,"version":"3.40.5"},"reference-count":65,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2023,12,2]]},"DOI":"10.1080\/14712598.2023.2287097","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T08:51:40Z","timestamp":1700556700000},"page":"1255-1263","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Biological therapy in polymyalgia rheumatica"],"prefix":"10.1080","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4687-5780","authenticated-orcid":false,"given":"Daniel","family":"Wendling","sequence":"first","affiliation":[{"name":"Rheumatology, CHU (University Teaching Hospital), Besan\u00e7on, France"},{"name":"EA4266 EPILAB, Universit\u00e9 de Franche-Comt\u00e9, Besan\u00e7on, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,11,23]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01310-7"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31825-1"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.04.001"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23132"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200329"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2014.04.007"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew202"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-00976-8"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead189"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152017"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207492"},{"key":"e_1_3_4_14_1","first-page":"ard-2022","article-title":"Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica","volume":"24","author":"Dejaco C","year":"2023","unstructured":"Dejaco C, Kerschbaumer A, Aletaha D, et al. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis. 2023 Feb;24:ard-2022\u2013223429","journal-title":"Ann Rheum Dis"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1757-y"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.05.003"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac050"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep395"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05819-z"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-022-00976-0"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.55.4.218"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-141-7-200410050-00005"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152110"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102670"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06708-3"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/gdps1r"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.011379"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex477"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12030329"},{"issue":"4","key":"e_1_3_4_30_1","first-page":"760","article-title":"Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study","volume":"30","author":"Salvarani C","year":"2003","unstructured":"Salvarani C, Cantini F, Niccoli L, et al. Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study. J Rheumatol. 2003 Apr;30(4):760\u2013763.","journal-title":"J Rheumatol"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23095"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-011-1914-z"},{"issue":"6","key":"e_1_3_4_33_1","first-page":"373","article-title":"TNF-alpha blockade induce clinical remission in patients affected by polymyalgia rheumatica associated to diabetes mellitus and\/or osteoporosis: a seven cases report","volume":"9","author":"Migliore A","year":"2005","unstructured":"Migliore A, Massafra U, Carloni E, et al. TNF-alpha blockade induce clinical remission in patients affected by polymyalgia rheumatica associated to diabetes mellitus and\/or osteoporosis: a seven cases report. Eur Rev Med Pharmacol Sci. 2005 Nov;9(6):373\u2013378.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-9-200705010-00005"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3140"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-008-1026-6"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091185"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21750"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3182a6aa0e"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.01.003"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000162"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150599"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2650-y"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-018-4086-1"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132948"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead426"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208742"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3287-z"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1499-2"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2020.105117"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39740"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13723"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.03.006"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221126"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.15459"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303452"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00245-9"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00032-2"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.210455"},{"key":"e_1_3_4_60_1","unstructured":"Abatacept in earLy Onset Polymyalgia Rheumatica: Study ALORS (ALORS). https:\/\/beta.clinicaltrials.gov\/study\/NCT03632187"},{"key":"e_1_3_4_61_1","unstructured":"Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica. 2023. https:\/\/clinicaltrials.gov\/study\/NCT05533125"},{"key":"e_1_3_4_62_1","unstructured":"Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse. 2023. https:\/\/clinicaltrials.gov\/study\/NCT05533164"},{"key":"e_1_3_4_63_1","unstructured":"Phase III study of efficacy and safety of secukinumab versus placebo in combination with Glucocorticoid taper regimen in patients with polymyalgia rheumatica (PMR) (REPLENISH). https:\/\/beta.clinicaltrials.gov\/study\/NCT05767034"},{"key":"e_1_3_4_64_1","unstructured":"Kevzara\u00ae (sarilumab). Approved by FDA as first and only biologic indicated for patients with polymyalgia rheumatica | regeneron pharmaceuticals inc. https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/kevzarar-sarilumab-approved-fda-first-and-only-biologic\/."},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209596"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2023.03.005"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004249"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2023.2287097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T19:31:53Z","timestamp":1727206313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2023.2287097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,23]]},"references-count":65,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,2]]}},"alternative-id":["10.1080\/14712598.2023.2287097"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2023.2287097","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"type":"print","value":"1471-2598"},{"type":"electronic","value":"1744-7682"}],"subject":[],"published":{"date-parts":[[2023,11,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-10-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}